ONSURA Trademark

Trademark Overview


On Wednesday, October 11, 2017, a trademark application was filed for ONSURA with the United States Patent and Trademark Office. The USPTO has given the ONSURA trademark a serial number of 87641241. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, March 28, 2022. This trademark is owned by Teva Pharmaceuticals USA, Inc.. The ONSURA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations for the prevention and treatment of alzheimer's disease; pharmaceutical preparations for the prevention and treatment of depression; pharmaceutical preparations for the prevention and treatment of psychological disorders; pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; pharmaceutical preparations for the prevention and treatment of osteoporosis; pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; pharmaceutical preparations for the prevention and treatment of ...
onsura

General Information


Serial Number87641241
Word MarkONSURA
Filing DateWednesday, October 11, 2017
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, March 28, 2022
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 25, 2018

Trademark Statements


Goods and ServicesPharmaceutical preparations for the prevention and treatment of alzheimer's disease; pharmaceutical preparations for the prevention and treatment of depression; pharmaceutical preparations for the prevention and treatment of psychological disorders; pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; pharmaceutical preparations for the prevention and treatment of osteoporosis; pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; pharmaceutical preparations for the prevention and treatment of digestive tract, gastrointestinal and dermatological diseases and disorders; pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; pharmaceutical preparations for the prevention and treatment of sexual dysfunction; pharmaceutical preparations for the prevention and treatment of symptoms associated with uterine fibroids; pharmaceutical preparations for the prevention and treatment of urinary incontinence and overactive bladder; pharmaceutical preparations for the prevention and treatment of aids-related disorders; pharmaceutical preparations that support, encourage and promote bone strength; pharmaceutical preparations that support, encourage and promote bone health; pharmaceutical preparations used in the treatment of bone disorders and bone diseases; pharmaceutical preparations, namely, injectable contraceptives; pharmaceutical preparations, namely, contraceptive preparations; pharmaceutical preparations, namely, fertility enhancement preparations; pharmaceutical preparations, namely, hormone replacement therapy preparations; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations, namely, pharmaceutical agents affecting the central nervous system; pharmaceutical preparations, namely, pharmaceutical agents affecting circulatory systems; pharmaceutical preparations, namely, pharmaceutical agents affecting sensory organs; pharmaceutical preparations, namely, pharmaceutical agents affecting urogenital organs; pharmaceutical preparations, namely, pharmaceutical agents affecting peripheral nervous system

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, October 18, 2017
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameTeva Pharmaceuticals USA, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressParsippany, NJ 07054

Party NameTeva Pharmaceuticals USA, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNorth Wales, PA 19454

Trademark Events


Event DateEvent Description
Monday, March 28, 2022ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, March 28, 2022ABANDONMENT - NO USE STATEMENT FILED
Tuesday, August 10, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, August 9, 2021SOU EXTENSION 5 GRANTED
Wednesday, August 4, 2021SOU EXTENSION 5 FILED
Monday, August 9, 2021CASE ASSIGNED TO INTENT TO USE PARALEGAL
Wednesday, August 4, 2021SOU TEAS EXTENSION RECEIVED
Saturday, February 13, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, February 11, 2021SOU EXTENSION 4 GRANTED
Thursday, February 11, 2021SOU EXTENSION 4 FILED
Thursday, February 11, 2021SOU TEAS EXTENSION RECEIVED
Saturday, August 15, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, August 13, 2020SOU EXTENSION 3 GRANTED
Thursday, August 13, 2020SOU EXTENSION 3 FILED
Thursday, August 13, 2020SOU TEAS EXTENSION RECEIVED
Saturday, February 29, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, February 19, 2020SOU EXTENSION 2 GRANTED
Wednesday, February 19, 2020SOU EXTENSION 2 FILED
Wednesday, February 19, 2020SOU TEAS EXTENSION RECEIVED
Friday, August 16, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, August 14, 2019SOU EXTENSION 1 GRANTED
Wednesday, August 14, 2019SOU EXTENSION 1 FILED
Wednesday, August 14, 2019SOU TEAS EXTENSION RECEIVED
Tuesday, August 13, 2019ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, August 13, 2019TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, February 19, 2019NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, December 25, 2018OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, December 25, 2018PUBLISHED FOR OPPOSITION
Wednesday, December 5, 2018NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Friday, November 16, 2018APPROVED FOR PUB - PRINCIPAL REGISTER
Tuesday, November 13, 2018TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, November 13, 2018CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, November 6, 2018ASSIGNED TO LIE
Friday, October 26, 2018TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Tuesday, August 7, 2018NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Tuesday, August 7, 2018LETTER OF SUSPENSION E-MAILED
Tuesday, August 7, 2018SUSPENSION LETTER WRITTEN
Thursday, July 12, 2018TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, July 11, 2018CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, July 11, 2018TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, January 16, 2018NOTIFICATION OF NON-FINAL ACTION E-MAILED
Tuesday, January 16, 2018NON-FINAL ACTION E-MAILED
Tuesday, January 16, 2018NON-FINAL ACTION WRITTEN
Wednesday, January 10, 2018ASSIGNED TO EXAMINER
Wednesday, October 18, 2017NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, October 14, 2017NEW APPLICATION ENTERED